Comparative analysis of amino acid profiles across pediatric groups stratified by asthma and IgE-dependent allergy showed differences in serum asparagine levels Authors: Natalia Rzetecka-Mańka, Martyna Pajewska-Szmyt, Joanna Matysiak, Paulina Sobkowiak, Irena Wojsyk-Banaszak, Anna Bręborowicz, Szymon Plewa, Dagmara Pietkiewicz, Jan Matysiak, Agnieszka Klupczyńska-Gabryszak Published: 2026 ABSTRACT AbstractBackgroundAlthough childhood asthma and IgE-dependent allergy frequently co-occur, the characterization of amino acid profiles associated with these conditions remains incomplete. The diagnosis of asthma and IgE-dependent allergy in children under five years of age is mainly based on clinical criteria, repeated specialist assessments, therapeutic response, and the exclusion of alternative causes, with functional testing performed when feasible. Therefore, identifying molecular indicators could improve the characterization and diagnosis of asthma in pediatric patients.Materials and methodsThe study included 113 serum samples from pediatric children. The study examined a comprehensive profile of free amino acids among four groups of children aged six months to five years. Three study groups were analyzed: children with asthma, children with asthma and IgE-dependent allergies, and children with IgE-dependent allergies along with one control group without asthma and IgE-dependent allergy. The targeted metabolomic analysis was performed using the Chromsystems kit. Samples were analyzed using a triple quadrupole tandem mass spectrometer coupled with a high-performance liquid chromatograph. Then, univariate statistical analyses were performed.ResultsThe method enabled quantification of 26 amino acids. The statistical analysis was conducted using the Mann-Whitney U and t-test. A significant difference in one amino acid concentration was found between patients with asthma and those with asthma and IgE-dependent allergy - asparagine (p-value 0.025). In addition, two amino acids distinguished the children with asthma from the control group: alpha-aminobutyric acid (p-value 0.011) and asparagine (p-value 0.017).ConclusionsThe research suggests a potential connection between asparagine levels and childhood asthma, as well as asthma with IgE-dependent allergy. This study involving four groups of pediatric patients may provide a basis for further scientific research into the role of amino acids, particularly asparagine, in n the molecular mechanisms underlying asthma.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s11306-026-02533-2.Keywords: Amino acids, Asthma, Allergy, Pediatric, Asparagine, Alpha-aminobutyric acid Introduction Asthma is a chronic inflammatory disease of the airways characterised by bronchial hyperreactivity. It is a heterogeneous disease that can present with different phenotypes and endotypes. The “phenotype” is defined as the set of observable clinical features of a disease due to the interaction of genetic, environmental, and lifestyle factors. By contrast, an “endotype” refers to the specific pathophysiological mechanism responsible for the development and progression of disease (Agache & Akdis, 2016). Consequently, patient classification considers not only clinical phenotypes, but also endotypes, the molecular basis of diseases. The most common symptoms of asthma are recurrent coughing, wheezing, breathing difficulties, and chest pain (Foppiano & Schaub, 2023). Asthma can also occur alongside various diseases, including allergies and atopic dermatitis (Rzetecka et al., 2025, p.). IgE-dependent allergies are primarily predicated on the concentration of specific IgE antibodies in the blood. However, the pathogenesis of allergic diseases in asthma cannot be based solely on an IgE-dependent mechanism, in which activation upon allergen exposure leads to an immediate allergic reaction. Instead, the result of a multitude of interactions between T helper 2 cells and T regulatory cells is imperative for the progression of allergic diseases and their subsequent treatment (Jutel et al., 2006). Peripheral T-cell tolerance, facilitated by immunoregulatory cytokines such as IL-10 and TGF-β, is crucial for maintaining a normal immune response and effectively controlling allergic diseases (Jutel et al., 2006). Similar phenotypic symptoms may result from different molecular and cellular mechanisms, which is why identifying asthma and allergy endotypes is increasingly important for a better understanding of the disease. Additionally, various factors contribute to the development of asthma, including genetic and environmental factors (Pajewska-Szmyt et al., 2025). Recently, there has been increasing discussion and research into the correlations between asthma and environmental factors (Chatkin et al., 2022; Krishnan & Panacherry, 2018; Mukherjee & Zhang, 2011; Pajewska-Szmyt et al., 2025; I. V. Yang et al., 2017). Along with technological development, the body’s exposure to air pollution has increased. In addition, children whose immune systems are still developing will be particularly vulnerable (Sly & Carpenter, 2012). The ongoing climate change undoubtedly contributes to the intensification of the problem (Burbank, 2025). The diagnosis of asthma in adults, adolescents, and children aged 6 years and older is well classified according to the Global Initiative for Asthma (“Global Initiative for Asthma” n.d.). However, diagnosing very young children (six months to five years old) can be challenging, as methods such as spirometry are typically used for older children (Matysiak et al., 2020). Moreover, in children under 3 years of age, it is also not possible to perform a respiratory system test such as oscillometry, and the diagnosis of asthma is therefore based solely on clinical symptoms (Ducharme & Chan, 2025; Kaminsky et al., 2022). For this reason, there is a growing trend in research to identify indicators that matter for diagnosing childhood asthma, when functional pulmonary testing is limited or not feasible. Omics studies, including metabolomics, aim to provide thorough analyses of the mechanisms occurring within organisms by enabling the tracking of biological pathways and the discovery of asthma biomarkers (Rzetecka et al., 2025; Zhang et al., 2011). The human metabolome comprises a diverse array of compounds, including lipids, sugars, amino acids, fatty acids, nucleic acids, organic acids, vitamins, and hormones, which undergo numerous changes (Zhang et al., 2011). Metabolites, as “small” pieces of the puzzle contain a wealth of information about the functioning of the human body, both in health and disease, and even the smallest change can provide a clue for proposing targeted therapies. Although all groups of metabolites are crucial and perform important functions in the body, this work focuses on the analysis of amino acids (AAs), which are the building blocks of proteins and also participate in the regulation of intracellular signalling, including participation in the proliferation, differentiation, and activation of immune cells (Ling et al., 2023). AAs are divided into two groups: proteinogenic and non-proteinogenic, depending on whether they are building blocks of proteins or not, respectively. There are 22 proteinogenic AAs incorporated into protein structure during translation, of which 20 are encoded in the genetic code (Ayon, 2020). Additionally, AAs are divided into two types: endogenous, which can be synthesized by the body itself, and exogenous, which the body cannot synthesize and must therefore obtain through diet. The objective of the present study was to determine the broad amino acid profiles in serum samples from 113 children, aged six months to five years. This study includes four patient groups: children with asthma (As); children with asthma and IgE-dependent allergy (As + Al); children with IgE-dependent allergy (Al); and one control group of children without asthma and IgE-dependent allergy (C). To the best of our knowledge, this is the first study to utilize four groups of young patients (six months to five years) and to measure a wide range of AAs in this disease entity. The present study addresses a gap in the current literature by providing a comprehensive assessment of amino acid profiles in children with asthma and IgE-dependent allergy. The results of the study appear exploratory and provide novel insights into the mechanisms underlying asthma and asthma with allergies. This provides a scientific basis for further research into potential indicators for the targeted diagnosis of childhood asthma. Materials and methods Study subjects Serum samples were collected from childhood patients aged six months to five years. A group of childhood patients was divided into four groups: patients with asthma (As) (n = 29), patients with asthma and IgE-dependent allergy (As + Al) (n = 37), patients with IgE-dependent allergy (Al) (n = 20), and control patients without asthma and IgE-dependent allergy (C) (n = 27) (Fig. 1). Written informed consent for sample collection was provided by all parents or guardians of the study participants. This research was conducted in accordance with the Declaration of Helsinki (Sawicka-Gutaj et al., 2022) and was approved by the Bioethics Committee of Poznań Medical University, Poland (decision no. 960/22). Workflow with box plots that show significant differences in amino acid levels between the investigated groups of preschool children. Orange- group with asthma; purple- group with asthma and allergy; green- non-asthmatic and non-IgE-allergic control group. A In the comparison of children with asthma vs. children with asthma and IgE-dependent allergy – asparagine (p-value 0.025); B In the comparison of children with asthma vs. non-asthmatic and non-IgE-allergic control group - asparagine (p-value 0.017); C In the comparison of children with asthma vs. non-asthmatic and non-IgE-allergic control group - alpha-aminobutyric acid (p-value 0.011). Created with BioRender.com The diagnosis of medical conditions, such as asthma, asthma with allergy, and allergies, was made by a pediatric allergist. Main criterion of inclusion in the study group with asthma were as follows: presence of at least 3 episodes of bronchial obstruction (expiratory wheezing, coughing, shortness of breath, and difficulty breathing), additional documented improvement following the administration of short-acting beta-agonists (SABA) or a single but severe episode of bronchial obstruction requiring systemic steroids and/or hospitalisation, followed by improvement after 2–3 months of inhaled glucocorticosteroid therapy. The symptoms to be considered were wheezing, shortness of breath, and cough caused by physical activity, playing, laughing, or crying, as well as the exclusion of other causes of wheezing and the occurrence of atopic diseases and/or asthma in the family, particularly in parents. Bronchial obstruction was additionally confirmed using forced oscillometry in children who were able to fully cooperate. Forced oscillometry can be used to measure respiratory function and airway resistance in children over three years of age who are unable to perform with standard methods, such as spirometry. To confirm an asthma diagnosis, each patient was evaluated by a specialist at least twice (mainly three times) over a six-month observation period. The diagnosis of an allergy was based on the consistency between clinical symptoms and positive IgE results confirming the allergy. Serum blood samples were examined for total immunoglobulin E (IgE), immunoglobulin M (IgM), immunoglobulin G (IgG), and immunoglobulin A (IgA) concentrations in patients included in the research. IgE antibodies to 30 selected allergens were also determined using the Atopic Polycheck 30-I panel (Biocheck, Münster, Germany). The study included four groups of patients: (As) those with symptoms indicative of bronchial asthma, (As + Al) those with the same asthma symptoms and an IgE-dependent allergy, (Al) those with only an IgE-dependent allergy, and (C) a control group of children with recurrent respiratory infections but no clinical signs of bronchial asthma. Participants were recruited from the Department of Pediatric Pneumonology, Allergology and Clinical Immunology, K. Jonscher Clinical Hospital, Poznań University of Medical Sciences, and the medical practice of Joanna Matysiak in Kalisz. Sample collection Serum samples were collected from 113 children (Table 1) during medical examinations in the Department of Pediatric Pneumonology, Allergology and Clinical Immunology, K. Jonscher Clinical Hospital, Poznań University of Medical Sciences, and the medical practice of Joanna Matysiak in Kalisz. First blood was collected into 7.5 mL tubes containing a clotting activator (S-Monovette Serum Gel CAT, Sarstedt, Nümbrecht, Germany), and then centrifuged at 2500×g for 10 min at 20 °C to obtain serum samples. All samples were stored at − 80 °C prior to analysis. Table 1Patient characterizationPatients with asthma and IgE-dependent allergyPatients with asthmaPatients with IgE-dependent allergy, without asthmaControl patients without asthma and IgE-dependent allergyNo. of subjects37292027Female1212715Male25171312 Age (year) Median3.63.34.02.8Range1.3–4.90.8–4.91.9–4.90.5–4.9Mean ± SD2.7 ± 1.12.6 ± 1.33.4 ± 0.82.6 ± 1.3 Immunoglobulins IgA (g/L) Range0.20–2.100.07–1.200.28–1.350.20–1.80Mean ± SD0.65 ± 0.410.54 ± 0.270.72 ± 0.310.64 ± 0.43 IgM (g/L) Range0.25–1.770.19–1.220.27–1.700.19–1.30Mean ± SD0.89 ± 0.420.70 ± 0.320.89 ± 0.420.79 ± 0.42 IgG (g/L) Range5.18–14.004.90–10.603.00–13.401.30–9.80Mean ± SD8.03 ± 2.897.70 ± 2.088.15 ± 2.107.27 ± 2.88 IgE (kU/I) Range1.00–1071.000.70–219.505.00–184.801.90–137.10Mean ± SD118.09 ± 201.0738.00 ± 44.8842.03 ± 43.0631.73 ± 35.66 Allergy Allergy classes based on IgE concentration (%) Class 289.19-100.00-Class 332.43-63.16-Class 418.92-26.32-Class 58.11-10.53-Class 65.41-5.26- Most common allergies (%) 6-grass mix29.7-20.0-Apple43.2-35.0-Birch pollen13.5-15.0-Cat dander32.4-70.0-CCD/Bromelain27.0-25.0-Cocoa10.8-25.0- Dermatophagoides farinae 18.9-15.0- Dermatophagoides pteronyssinus 18.9-25.0-Dog dander75.7-65.0-Mugwort pollen16.2-15.0-Rye24.3-10.0- Patient characterization Samples and reagents preparation The samples were prepared according to the manufacturer’s instructions (MassChrom® Amino Acid Analysis kit (Chromsystem Instruments & Chemicals GmbH, Gräfelfing, Germany)), which is certified to ISO 9001 and ISO 13,485. The AA internal standard mixture was reconstituted with 5 mL of reconstitution buffer. Calibrators were reconstituted with 0.5 mL of distilled water, and the control samples (QCs) were reconstituted with 1 mL of distilled water. The reconstituted samples were then swirled repeatedly for 15 min. Frozen serum samples were thawed on the day of analysis and then homogenized by intensive vortexing. Preparation of biological samples (serum), calibrators, and control samples followed the same steps. Firstly, 25 µl of serum/calibrator/control sample was pipetted into a 1.5 mL Eppendorf vial. Next, 50 µL of reconstituted internal standard mixture and 400 µl of precipitation reagent were added to each sample. The samples were then vortexed for 30 s and centrifuged for 5 min at 16,000 × g. Finally, 200 µL of supernatant was transferred to the LC autosampler vial. Analysis using LC-MS/MS (liquid chromatography-tandem mass spectrometry) For the quantification of AAs, a liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) system comprising a 1260 Infinity high-performance liquid chromatograph (HPLC) (Agilent Technologies, Santa Clara, CA, USA) coupled with a 5500 QTRAP mass spectrometer (Sciex, Framingham, MA, USA) was used. Autosampler racks with samples were protected from light and refrigerated. An analytical column from the Chromsystems kit was used for the separation of AAs, with a column temperature of 25 °C. The injection volume of the sample was 5 µL, and the total run time lasted 19 min with a flow rate of 0.3–1.8 mL/min: 0–14.9, 0.8mL/min; 15.0–15.8, 0.3mL/min; 15.9–17.4, 0.8mL/min; 17.5–18.7, 1.8mL/min; 18.8–18.9, 0.8mL/min. Separation was performed with following gradient: started with 100% phase A to 0.5 min, 89% phase A maintained to 5 min; 5–12 min from 89% to 83% phase A; 12–13 min from 83% to 73% phase A; 13–13.5 min from 73% to 0% maintained to 16.5 min; 16.6–16.6 min from 0% to 100% phase A maintained to 18.9 min. A QC sample was analyzed for every ten real samples. The detection of analytes was conducted at positive mode (electrospray ionization - ESI+). Analysis was performed in multiple reaction monitoring (MRM) scan mode (Table 1S). Data analysis At the first step, the obtained output was pre-treated to remove the data that did not meet the accepted criteria for statistical analysis. Firstly, metabolites that were determined below the limit of quantification (LOQ) in the samples (acetylotyrosine, homocystine, carnosine, phosphoethanolamine, adenosylhomocysteine, anserine, phosphoserine, and alloisoleucine) were removed. Next, metabolites with more than 15% missing data (cystathionine, argininosuccinic acid) were excluded. Missing values were replaced with half of the LOQ value for the appropriate AAs. The precision of measurements was calculated using the relative standard deviation (RSD) of QC samples, with values of less than 10% being recorded. Univariate statistical analyses were performed using PQStat software 2023 (PQStat v.1.8.6.126, Poznań, Poland), and GraphPad Prism 10 (10.6.1 (892), 2025). A p-value < 0.05 was considered statistically significant. The normality of data distribution was determined for each metabolite using the Shapiro-Wilk test, and the variance using the Levene test. Then, a comparison analysis between the groups was performed using the t-test for parametric data and the Mann-Whitney test for non-parametric data. Results The application of the LC-MS/MS-based methodology enabled the determination of 26 AAs in serum samples from pediatric patients (Table 1; Fig. 1). Metabolites that were determined below LOQ in the collected sera were removed from the subsequent statistical analysis. Out of the 21 proteinogenic AAs, 19 were quantified. Out of the 28 non-proteinogenic AAs, only 7 were quantified and processed for further analysis (21 non-proteinogenic AAs were below LOQ). To identify significant differences in AA concentrations between the analyzed groups, statistical analyses were conducted using the Mann-Whitney test or the t-test (Table 3). One of the most notable findings was in the comparison of As and As + Al, which revealed a significant difference in asparagine (Asn) (p-value 0.025) (Fig. 1-A, Table 3). In the comparison of patients with As vs. C, two AAs distinguished the mentioned groups - Asn (p-value 0.017) (Fig. 1-B, Table 3), and alpha-aminobutyric acid (AABA) (p-value 0.011) (Fig. 1-C, Table 3). Interestingly, the As group had a higher Asn and AABA concentration than the As + Al and C groups in each comparison. No other statistically significant differences were found (Fig. 1; Table 2). Table 3Summary of statistically significant differences between groupsCompared groupsDifferentiating amino acidsFold change(Average)p-valueChildren with asthma (As)Children with asthma and IgE-dependent allergy (As + Al)Asparagine1.210.025Children with asthma (As)Children with IgE-dependent allergy (Al)---Children with asthma (As)Control group without asthma and IgE-dependent allergy group (C)Alpha-aminobutyric acidAsparagine1.231.270.0110.017Children with asthma and IgE-dependent allergy (As + Al)Children with IgE-dependent allergy (Al)---Children with asthma and IgE-dependent allergy (As + Al)Control group without asthma and IgE-dependent allergy group (C)---Children with IgE-dependent allergy (Al)Control group without asthma and IgE-dependent allergy group (C)--- Summary of statistically significant differences between groups Alpha-aminobutyric acid Asparagine 1.23 1.27 0.011 0.017 Table 2Amino acid concentration (µM) determined in the collected serum samples - average, SD, median, Q1-Q3Amino acidGroup with asthma (As)Group with asthma and IgE-dependent allergy (As + Al)Group with IgE-dependent allergy, without asthma (Al)Control group without asthma and IgE-dependent allergy (C)Average ± SDMedian (Q1-Q3)Average ± SDMedian (Q1-Q3)Average ± SDMedian (Q1-Q3)Average ± SDMedian (Q1-Q3)1-Metylhistidine2.97 ± 1.182.65 (2.01–3.40)2.94 ± 1.262.58 (2.15–3.39)3.39 ± 1.742.96 (2.08–4.18)2.67 ± 1.182.34 (2.01–2.85)4-Hydroxyproline28.02 ± 12.5226.84 (20.43–31.82)25.56 ± 11.2423.25 (17.63–33.61)28.01 ± 9.7725.57 (21.45–34.06)26.78 ± 14.1524.35 (19.44–27.89)Alanine487.39 ± 147.27464.70 (377.80–576.90)469.82 ± 126.96458.80 (389–568.60)464.18 ± 135.24448.15 (395.02–514.62)490.92 ± 121.58466.90 (416.50–573.90)alpha-Aminobutyric acid22.56 ± 5.9422.01 (19.10–26.06)20.74 ± 7.0420.15 (16.25–24.06)21.88 ± 9.8919.56 (14.84–26.18)18.34 ± 6.1518.11 (14.94–21.40)Arginine150.85 ± 41.84149.6 (110.30–183.20)141.12 ± 47.77130.40 (110.40–162.20)133.42 ± 50.89124.75 (112.32–154.70)146.44 ± 57.81135.90 (113.95–162.15)Asparagine52.78 ± 17.8951.66 (43.58–65.15)43.71 ± 14.2645.75 (32.84–54.77)46.64 ± 22.2945.37 (33.74–58.51)41.28 ± 17.1240.76 (33.33–53.63)Aspartic acid41.70 ± 12.8142.98 (32.43–53.62)42.67 ± 15.9443.26 (33.49–54.44)41.46 ± 17.5839.90 (30.89–52.72)56.83 ± 42.6350.53 (38.33–54.67)Citrulline31.05 ± 9.5930.18 (25.14–37.57)31.92 ± 7.8430.97 (26.53–37.17)33.53 ± 9.4432.30 (24.49–40.01)30.82 ± 8.7631.01 (24.28–34.42)Ethanolamine12.14 ± 3.8211.37 (9.63–14.92)12.88 ± 4.8611.93 (10.04–15.77)13.00 ± 4.0212.09 (10.60–13.60)15.50 ± 7.3514.49 (11.50–17.71)Glutamic acid126.87 ± 51.86118.9 (111.70–158.90)136.425 ± 49.81134.50 (98.99–173.30)151.43 ± 114.95114.80 (96.19–147.25)160.27 ± 102.76142.60 (117.90–161.45)Glutamine531.04 ± 85.53542.40 (503.2–574.90)514.05 ± 88.82523.40 (471.60–576.30)480.14 ± 163.99515 (453.82–570.82)481.65 ± 137.60505.90 (446.85–562.20)Glycine365.45 ± 91.29380.30 (329.10–426.10)368.02 ± 85.92363 (324.40–418.40)373.18 ± 106.79371.20 (329.57–405.15)373.08 ± 94.33347.30 (303.75–444.40)Histidine103.99 ± 16.84103.40 (90.53–116.10)99.28 ± 19.85100 (84.04–109.20)106.01 ± 23.03100.71 (89.95–113.12)103.97 ± 26.5799.66 (84.96–116.20)Isoleucine79.09 ± 30.8277.29 (53.58–97.38)77.09 ± 32.5468.34 (55.59–85.76)76.81 ± 29.2966.37 (57.56–93.72)73.64 ± 25.1372.58 (55.66–83.94)Leucine148.49 ± 54.41137.10 (117.10–165.40)147.63 ± 50.74140.40 (111.80–173.50)144.62 ± 45.95136.80 (102.12–179.20)153.15 ± 61.00140.50 (118.25–167.95)Lysine215.57 ± 67.47223.10 (161.70–266.90)194.81 ± 68.24182 (149.90–218.60)196.85 ± 58.84187.10 (152.37–254.15)192.74 ± 59.33196.80 (135.60–228.55)Methionine35.84 ± 12.9534.25 (23.96–46.53)32.58 ± 13.6027.06 (24.59–37.37)31.63 ± 13.2327.23 (22.75–37.27)30.55 ± 10.8627.68 (22.62–37.04)Ornithine92.73 ± 28.6891.85 (73.43–121.40)88.97 ± 30.5887.86 (66.13–109.10)108.18 ± 45.8498.42 (78.83–118.50)104.68 ± 48.1796.36 (78.06–122.95)Phenylalanine105.51 ± 31.37106.2 (81.99–122.10)105.10 ± 28.55102.50 (92.24–125.20)106.32 ± 27.89109.75 (82.68–125.57)113.01 ± 33.61115.80 (87.93–127.50)Proline247.27 ± 96.60242.5 (187–276.20)255.83 ± 83.10243.80 (190.40–302.10)235.19 ± 65.37238.85 (190.90–274.70)259.20 ± 73.40259.90 (220.35–298.50)Serine222.12 ± 44.35227.50 (198.50–258.50)215.39 ± 45.03211.60 (196.10–240.30)219.30 ± 47.24219.85 (189.55–244.40)230.16 ± 73.35230 (179.30–253.20)Taurine109.30 ± 44.48101.70 (63.91–140)118.43 ± 46.47109.70 (87.17–135.10)118.79 ± 34.83121.5 (91.86–136.97)124.14 ± 49.96134.90 (79.51–172.75)Threonine142.73 ± 40.78143.30 (108.50–162.30)125.21 ± 32.04121.10 (103.90–144.80)131.76 ± 37.98120.75 (109.35–154.40)123.30 ± 42.36119.10 (84.64–148.90)Tryptophan70.05 ± 21.3862.51 (56.35–85.23)73.42 ± 19.3470.13 (64.51–77.80)73.66 ± 16.8470.93 (60.82–85.08)71.07 ± 17.0667.74 (60.45–80.20)Tyrosine88.06 ± 28.9781.71 (64.30–114)85.70 ± 30.8672.32 (65.55–101.10)80.83 ± 27.8273.44 (63.52–89.07)86.49 ± 32.0381.54 (62.55–102.05)Valine344.75 ± 93.56329.60 (269.40–395.70)338.70 ± 88.30305 (277.20–396.60)342.53 ± 99.70315.60 (261.27–412.10)336.41 ± 93.04314.60 (268.85–391.75) Amino acid concentration (µM) determined in the collected serum samples - average, SD, median, Q1-Q3 Discussion Recently, there has been a growing interest in exploring childhood asthma using a metabolomic approach (Table 4). As AAs are known to act as mediators of immune system activity (Packi et al., 2023), the present study compared them in serum samples to look for profile changes in children with asthma. The conducted research enabled quantification of 26 AAs in serum samples from 113 preschool children. To the best of our knowledge, this is the first study to compare four groups selected in this manner, which is particularly essential given that asthma often co-occurs with allergy (Crestani et al., 2020). Our studies identified significant change that could serve as a starting point for further metabolomic research of children with asthma and those with asthma and allergies- Asn; and in children with asthma vs. controls - AABA and Asn. Both discriminating compounds - Asn and AABA belong to the group of non-essential AAs, meaning they can be synthesized by organisms (Ayon, 2020). However, AABA belongs to non-protein AAs, while Asn is a component of the protein chain (Ding et al., 2020). Table 4Determination of amino acids in children with asthma in the literatureType of studySample Preparation/Instrumental methodStudy populationPatients ageMatrixThe main findingsReferencesTargeted metabolomics, AA analysisCommercial kit aTRAQ/LC-MS/MS13 children with asthmaMedianSerumChildren with asthma vs. control group: Taurine↓ L-valine↓DL-β-aminoisobutric acid↓γ- amino-n-butyric↑L-arginine ↑(Matysiak et al., 2020)12 years17 control patients10 yearsUntargeted metabolomicsProtein precipitation with MeOH/LC-MS/MS and GC-MS35 children with asthmaMedianSerumChildren with FA vs. control:Lysine, threonine, valine, isoleucine, glutamate Children with asthma vs. children with FA Aspartate, tyrosine, tryptophan, histidine Children with asthma vs. controls Lysine, leucine, valine, and threonine(Crestani et al., 2020)7.5 years35 children with food allergy (FA)4.1 years35 children with asthma and food allergy5.5 years20 control patients6.3 yearsUntargeted metabolomicsProtein precipitation with MeOH/LC-MS/MS144 children with asthma and atopyMeanPlasmaChildren with atopy and asthma vs. healthy patients:gamma-glutamyl amino acid↓, lysine↓, tryptophan↓(Lejeune et al., 2024)6.7 years74 children with asthma3.6 years42 children with atopy8.5 years210 children without asthma and atopy5.4 yearsUntargeted metabolomicsProtein precipitation with MeOH and ACN/LC-MS/MS174 non-exacerbation-prone asthmaMeanPlasmaNon-exacerbation-prone asthma group vs. exacerbation-prone asthma group:arginine↑, asparagine↑, citrulline↑, histidine↑, lysine↑, serine↑, tryptophan↑, valine↑, methionine↑, ornithine↑(Cottrill et al. 2023)11.67 years41 exacerbation-prone asthma11.70 yearsTargeted metabolomics, AA analysisCommercial kit – MassChrom® Amino Acid Analysis/LC-MS/MS29 children with asthmaMeanSerumPatients with asthma vs. those with asthma and IgE-dependent allergy: asparagine ↑Patients with asthma vs. control patients: alpha-aminobutyric↑ acid and asparagine↑Present study2.6 years37 children with asthma and IgE-dependent allergy2.7 years20 children with IgE-dependent allergy3.4 years27 children without asthma and IgE-dependent allergy2.6 years Determination of amino acids in children with asthma in the literature Children with asthma vs. control group: Taurine↓ L-valine↓ DL-β-aminoisobutric acid↓ γ- amino-n-butyric↑ L-arginine ↑ Children with FA vs. control: Lysine, threonine, valine, isoleucine, glutamate Children with asthma vs. children with FA Aspartate, tyrosine, tryptophan, histidine Children with asthma vs. controls Lysine, leucine, valine, and threonine Children with atopy and asthma vs. healthy patients: gamma-glutamyl amino acid↓, lysine↓, tryptophan↓ Non-exacerbation-prone asthma group vs. exacerbation-prone asthma group: arginine↑, asparagine↑, citrulline↑, histidine↑, lysine↑, serine↑, tryptophan↑, valine↑, methionine↑, ornithine↑ Patients with asthma vs. those with asthma and IgE-dependent allergy: asparagine ↑ Patients with asthma vs. control patients: alpha-aminobutyric↑ acid and asparagine↑ Asparagine Asn can be produced in the human body through a process known as asparagine biosynthesis. The main precursor of Asn is oxaloacetate, which is converted into aspartate by the enzyme transaminase (Yuan et al. 2024; Wishart et al. 2022). This enzyme plays a key role in transferring amino groups between AAs, which is essential for protein synthesis. The enzyme asparagine synthetase (ASNS) catalyzes the synthesis of Asn from aspartate, using glutamine as the amide group donor (requiring adenosine triphosphate (ATP)). Glutamine can also be further deaminated to support the tricarboxylic acid (TCA) cycle. Conversely, asparaginase (ASNase) hydrolyses Asn to produce aspartate (Yuan et al. 2024; Wishart et al. 2022). When Asn levels are low, the general control nonderepressible 2 (GCN2) pathway is activated. GCN2 is a serine-threonine protein kinase that is able to detect AA deficiencies by binding to uncharged transfer RNA (tRNA) (Zhao et al. 2023). This triggers the expression of ASNS, which initiates Asn synthesis and allows cells to survive the resulting stress (L. Yang et al. 2023). The biosynthesis of Asn enables the activation of CD8 + immune T cells, which include cytotoxic T cells and T memory cells (L. Yang et al. 2023). T cells are a type of immune system cell that plays a crucial role in protecting the body against infection. CD8⁺ T cells are one of the most essential types of lymphocytes in the immune system. Wu et al. (Wu et al. 2021) proved that Asn strongly influences the activation of CD8 + T cells (the higher the level of Asn, the stronger the activation). Reducing the consumption of products containing Asn or inhibiting the SLC1A5 transporter minimizes the response of CD8 + T cells. Furthermore, they suggest that tyrosine-protein kinase (LCK) is a natural sensor of Asn, signalling its sufficient amount for T cell function and enhancing phosphorylation at its activation site Tyr394, in TCR (T-cell Receptor) signalling. Hope et al. (Hope et al. 2021) observed that CD8 + T cells require an external intake of Asn in order to remain viable, grow, and initiate activation and metabolic reprogramming. If Asn or glutamine is missing, TCR stimulation causes significant T cell death. Additionally, Asn can partially compensate for the lack of glutamine, and vice versa. This is because TCR-stimulated T cells do not survive in the case of a combined deficiency of both AAs. In our research, we showed that serum Asn was significantly higher in the asthma group than in the non-asthmatic and non-IgE-allergic control group and in patients with asthma and allergies (Fig. 1; Table 3). The correlation between CD8 + cells and asthma may also be attributed to the presence of viral infections and other intracellular pathogens in the upper respiratory tract (Otter et al. 2016). In allergic asthma, the primary component of the immune response is caused by Th2 lymphocytes (Kim et al. 2013). The key cytokines are IL-4, IL-5, and IL-2, the last of which may be responsible for activating CD8 + T lymphocytes, thereby influencing the severity of inflammation. Consequently, elevated levels of Asn-associated CD8 + T cells may exacerbate and sustain asthma-related inflammation (Kim et al. 2013). Asn, a non-essential AA, has been hypothesised to serve as an indicator of asthma or related changes in the immune system, reflecting mechanisms that occur during inflammation. Our research suggests a potential connection between Asn and childhood asthma, which could enhance our understanding of the role of AAs in inflammatory diseases. Furthermore, this is the first study to use four patient groups in which Asn has been identified as a differentiating AA (Table 4). According to the literature, Asn is more recognized as a discriminative compound in oncology, particularly in cancer development and tumor progression (Hope and Salmond 2021; Jiang et al. 2021; Lorenzi et al. 2006), where cancer cells may require large amounts of Asn for proliferation (multiplication) (Krall et al. 2016). To the best of our knowledge, it has not been reported as a discriminatory feature in any respiratory disease. Alpha-aminobutyric acid AABA acid is produced as a by-product of methionine, threonine, serine, glycine and cysteine biosynthesis pathways. This AA can be found in various organs, including the kidneys and liver, as well as in biofluids, blood, breast milk, and urine (Wishart et al., 2022). Based on the literature, AABA is associated with liver disease, gut microbiome dysbiosis, and sepsis (Chiarla et al., 2011; Felicianna et al., 2025). Therefore, it has been suggested that a high-fat diet may increase AABA levels (Ismaiah et al., 2025). However, the article by Li et al. (Li et al., 2023) was the first to suggest the potential anti-inflammatory function of AABA in sepsis. They demonstrated that AABA inhibits the activation and pro-inflammatory function of M1 macrophages. This protects against sepsis induced by lipopolysaccharide or cecal ligation and puncture, as well as inflammatory bowel disease induced by dextran sulfate sodium. However, to our knowledge, no study has examined the link between AABA and childhood asthma. This is the first study to identify elevated AABA levels in young patients with asthma, prompting the presumption of its potential for group differentiation. This less obvious finding compels us to conduct further studies to bring us closer to understanding the relationship between AABA and asthma. Comparison of the study results with existing literature The growing problem of asthma is motivating researchers from various fields to perform studies which will help to understand the biological mechanisms and/or identify asthma-related metabolomic alterations. The previous metabolomic investigations of asthma indicated several alterations in AA profile in patients (Table 4). However, comparisons can be made in general terms, as different researchers used different study groups - including those with various conditions coexisting with asthma, such as atopic dermatitis (Crestani et al., 2020) or food allergies (Foong et al., 2017). The approaches to metabolomic analysis also differed, i.e., targeted and untargeted approaches. In this case, the targeted approach can be considered more specific because the sample preparation method focused on AAs. The literature also indicates that the type of sample collected differs between studies, specifically between serum and plasma (Table 4). In contrast to our findings, the three studies mentioned in Table 4 did not identify Asn and AABA as significant group discriminators. Only one study by Cottrill KA et al. (Cottrill et al., 2023), which compared non-exacerbation-prone and exacerbation-prone asthma patients, found higher Asn concentrations in the former group. Our study showed that children with asthma have higher levels of Asn than children with asthma and IgE-dependent allergy. Another statistically significant difference in Asn concentration that we found was between patients with asthma and the control group. However, in studies conducted by Crestani et al. (Crestani et al., 2020) and Matysiak et al. (Matysiak et al., 2020) comparing asthma and control groups, Asn was not found to be a differentiating factor. However, attention should also be paid to the fact that arginine, known as a typical AA biomarker of asthma (Benson et al., 2011; Xu et al., 2017), is not a distinguishing compound in our studies. Nevertheless, it is important to note that this AA did not differentiate in studies conducted by Crestani et al. (Crestani et al., 2020) and Lejeune et al. (Lejeune et al., 2024), which also examined patients with food allergies and atopy. This differs from the studies conducted by Matysiak et al. (Matysiak et al., 2020) and Cottrill et al. (Cottrill et al., 2023), which concluded that arginine is one of the AAs that distinguishes between the two groups (children with asthma vs. control; non-exacerbation-prone asthma group vs. exacerbation-prone asthma). The differences between studies involving AA analysis highlight the complexity of the problem and the numerous factors that can influence asthma heterogeneity, including various allergic symptoms. This finding is particularly interesting in the context of allergic sensitization, which is usually assessed using various clinical and laboratory parameters. In clinical practice, the assessment of allergic sensitization is commonly accompanied by laboratory investigations, including inflammation-related hematologic parameters. Previous pediatric studies have examined the relationships between allergen sensitization, laboratory parameters, and inflammatory markers in children with asthma and/or allergic rhinitis (Alkaya et al., 2026). These findings highlight the clinical value of integrating biochemical indicators with systemic inflammatory profiles to achieve a more comprehensive understanding of the mechanisms underpinning disease, and to improve patient characterization of allergic airway diseases. This is why the results of our study are particularly important for supporting the diagnosis in childhood patients. To our knowledge, there are limited scientific studies involving samples from children with asthma under five years old. This may be due to the difficulty of obtaining biological samples from childhood patients. The objective of the present study was to determine the broad amino acid profiles in serum samples from 113 children, aged six months to five years. This study includes four patient groups: children with asthma (As); children with asthma and IgE-dependent allergy (As + Al); children with IgE-dependent allergy (Al); and one control group of children without asthma and IgE-dependent allergy (C). To the best of our knowledge, this is the first study to utilize four groups of young patients (six months to five years) and to measure a wide range of AAs in this disease entity. The present study addresses a gap in the current literature by providing a comprehensive assessment of amino acid profiles in children with asthma and IgE-dependent allergy. The results of the study appear exploratory and provide novel insights into the mechanisms underlying asthma and asthma with allergies. This provides a scientific basis for further research into potential indicators for the targeted diagnosis of childhood asthma. Consequently, it is worthwhile to consider additional research steps based on the obtained outputs from the above study. Limitations of the study The performed research contributes significantly to the body of knowledge on the metabolomic profile of children with asthma. However, due to the relatively small sample size in each group, the results should be considered as exploratory. The reported p-values should also be interpreted with caution, given multiple comparisons, and the findings require validation in independent cohorts. It should also be noted that the control group in the study included children with recurrent respiratory infections, which may influence the metabolomic profile. However, this does not affect the validity of the results obtained or their interpretation. Nevertheless, careful consideration should be taken in comparing these results with those where the control group included study participants without any diagnosed medical condition. Additionally, serum amino acid concentrations can be influenced by numerous confounding factors, such as diet, age, concurrent infections, or medications. Recommendations for future research Future research should focus on targeted analyses of significantly larger groups of participants. Particular attention should be paid to the analysis of the amino acids found in this study: Asn and AABA. This could support the early stratification of asthma risk or aid the differential diagnosis of asthma phenotypes in preschool children. Therefore, future studies involving asthma subgroups defined by specific clinical characteristics may provide a more precise interpretation of the observed findings. A valuable direction for future research would be the integration of metabolomic findings with other omics approaches, which may provide deeper insight into the biological processes underlying the observed changes. Furthermore, as children under five have different dietary needs, the next step in our research should be to monitor changes in AA levels in relation to age and diet. Taken together, these future research directions could offer a more thorough understanding of the biological processes underlying childhood asthma and IgE-dependent allergies, and may serve a basis for further validation and mechanistic studies. Conclusions In the present study, the differences in serum Asn and AABA levels were found among selected clinical groups of preschool children. The research suggests a potential connection between Asn and childhood asthma, which could enhance our understanding of the role of AAs in inflammatory diseases. The study showed alterations in Asn level in asthma patients compared to patients with asthma with allergy and a non-asthmatic and non-allergic control group, but also raises the following question: Is Asn an indicator of active disease or perhaps of its effects resulting from changes in the respiratory system? To address the above question, extensive studies are required to investigate the correlations between metabolomic findings and molecular pathway analyses, particularly those related to the immune response. These findings may provide a basis for further studies investigating amino acid metabolism in childhood asthma and asthma with IgE-dependent allergy. In summary, this study contributes to existing literature by providing new evidence of the correlation between Asn and asthma, as well as offering a more refined diagnostic perspective. Supplementary Information Below is the link to the electronic supplementary material. Supplementary material 1 (DOCX 226.4 kb) Acknowledgements This study was funded by Grant No. 2021/43/O/NZ5/00480 from the National Science Centre, Poland. Author contributions N.R-M. writing – original draft. M.P-S., J.M., P.S., I.W-B., A.B., S.P., D.P., Jan.M. and A.K-G. writing – review and editing. N.R-M., M.P-S., S.P., D.P., A.K-G. methodology. N.R-M., M.P-S., J.M, P.S., I.W-B., A.B., Jan.M., A.K-G. investigation. N.R-M. visualization. N.R-M. software. Jan.M., A.K-G. conceptualization. Jan.M., A.K-G. supervision. Jan.M funding acquisition. All authors read and approved the final manuscript. Funding This study was funded by Grant No. 2021/43/O/NZ5/00480 from the National Science Centre, Poland. Data availability All data generated during this study are included in this published article and its supplementary information files. Declarations Competing interests The authors declare no competing interests. Declaration of generative AI and AI-assisted technologies in the manuscript preparation process During the preparation of this work, the authors used DeepL, Microsoft 365 Copilot, Grammarly in order to language and stylistic correction. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary material 1 (DOCX 226.4 kb) Data Availability Statement All data generated during this study are included in this published article and its supplementary information files.